Trial Profile
A Phase 1B Study of Donafenib Monotherapy in Advanced Oesophageal Cancer Progressing After Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Donafenib (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 13 Jun 2023 Status changed to discontinued, according to ClinicalTrials.gov: US National Institutes of Health record.
- 28 Nov 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2024.
- 28 Nov 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Mar 2024.